Status:
COMPLETED
Involvement of SK3 Calcium Channel in Taxane Neuropathy
Lead Sponsor:
University Hospital, Tours
Conditions:
Breast Cancer
Chemotherapy-induced Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Brief Summary
Taxane neuropathy is a common and long-term side effect of long-term morbidity in patients surviving cancer. No preventive or symptomatic treatment has been shown to be effective. Its pathophysiology ...
Detailed Description
Patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or pro...
Eligibility Criteria
Inclusion
- Breast Group
- Age ≥ 18 years
- Breast cancer
- Chemotherapy with paclitaxel or docetaxel
- Adjuvant or neoadjuvant chemotherapy in localized cancer or first-line treatment in metastatic cancer
- Signed informed consent
- Prostate Group
- Age ≥ 18 years
- Metastatic prostate cancer
- Chemotherapy with docetaxel in 1st line
- Signed informed consent
Exclusion
- Anteriority or concomitance of another chemotherapy provider of neuropathy (platinum salts)
- Another possible cause of neuropathy: diabetes, alcoholism, vitamin B9 / B12 deficiency, neurodegenerative disease, Raynaud's syndrome
Key Trial Info
Start Date :
February 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 12 2020
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT03816904
Start Date
February 6 2019
End Date
June 12 2020
Last Update
April 28 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, Hospital, Chinon
Chinon, France, 37500
2
Department of Medical Oncology, University Hospital, Tours
Tours, France, 37044